Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.43
- Piotroski Score 6.00
- Grade Buy
- Symbol (AMGN)
- Company Amgen Inc.
- Price $287.86
- Changes Percentage (2.83%)
- Change $7.91
- Day Low $278.62
- Day High $288.48
- Year High $346.85
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Last Earnings 10/25/2024
- Ex-Dividend for 5/16 Dividend 11/18/2024
- Dividend Payable 12/09/2024
- Today N/A
- Next Earnings (Estimated) 02/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $307.00
- High Stock Price Target $405.00
- Low Stock Price Target $182.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $7.00
- Trailing P/E Ratio 43.57
- Forward P/E Ratio 43.57
- P/E Growth 43.57
- Net Income $6.72 B
Income Statement
Quarterly
Annual
Latest News of AMGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period
Amgen Inc. (NASDAQ: AMGN) shareholders saw a 13% drop in share price last week, yet the company's three-year returns were strong at 38%, surpassing the market index. Despite a decline in earnings per ...
By Yahoo! Finance | 5 days ago -
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy Right Now?
The pharmaceutical industry is witnessing a shift towards weight-loss drugs like Ozempic and Wegovy, showing potential in treating addiction and conditions like Alzheimer's. Despite challenges like fu...
By Yahoo! Finance | 2 weeks ago -
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
Amgen Inc's recent 10-Q filing reveals a strong financial performance with increased product sales driven by volume growth and strategic acquisitions. The company's resilience in navigating challenges...
By Yahoo! Finance | 2 weeks ago
